132 related articles for article (PubMed ID: 32943751)
1. Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study.
Yang Y; Wang Y; Liu X; He X; Zhang LL; Wu G; Qu BL; Qian LT; Hou XR; Zhang FQ; Qiao XY; Wang H; Li GF; Zhu Y; Cao JZ; Wu JX; Wu T; Zhu SY; Shi M; Xu LM; Su H; Song YQ; Zhu J; Zhang YJ; Huang HQ; Hu C; Qi SN; Li YX
Leukemia; 2021 Jun; 35(6):1671-1682. PubMed ID: 32943751
[TBL] [Abstract][Full Text] [Related]
2. Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials.
Maurer MJ; Habermann TM; Shi Q; Schmitz N; Cunningham D; Pfreundschuh M; Seymour JF; Jaeger U; Haioun C; Tilly H; Ghesquieres H; Merli F; Ziepert M; Herbrecht R; Flament J; Fu T; Flowers CR; Coiffier B
Ann Oncol; 2018 Aug; 29(8):1822-1827. PubMed ID: 29897404
[TBL] [Abstract][Full Text] [Related]
3. Outcome and risk prediction of early progression in patients with extranodal natural killer/T cell lymphoma from the CLCG study.
Li JY; Hou XR; Chen SY; Liu X; Zhong QZ; Qian LT; Qiao XY; Wang H; Zhu Y; Cao JZ; Wu JX; Wu T; Zhu SY; Shi M; Zhang HL; Zhang XM; Su H; Song YQ; Zhu J; Zhang YJ; Huang HQ; Wang Y; He X; Zhang LL; Qu BL; Yang Y; Hu C; Deng M; Wang SL; Qi SN; Li YX
Ann Hematol; 2023 Sep; 102(9):2459-2469. PubMed ID: 37306711
[TBL] [Abstract][Full Text] [Related]
4. Effect of primary tumor invasion on treatment and survival in extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: a multicenter study from the China Lymphoma Collaborative Group (CLCG).
Qi SN; Xu LM; Yuan ZY; Wu T; Zhu SY; Shi M; Su H; Wang Y; He X; Zhang LL; Wu G; Qu BL; Qian LT; Hou XR; Zhang FQ; Zhang YJ; Zhu Y; Cao JZ; Lan SM; Wu JX; Yang Y; Li YX
Leuk Lymphoma; 2019 Nov; 60(11):2669-2678. PubMed ID: 31060406
[TBL] [Abstract][Full Text] [Related]
5. Risk-dependent curability of radiotherapy for elderly patients with early-stage extranodal nasal-type NK/T-cell lymphoma: A multicenter study from the China Lymphoma Collaborative Group (CLCG).
Chen B; Zhu SY; Shi M; Su H; Wang Y; He X; Xu LM; Yuan ZY; Zhang LL; Wu G; Qu BL; Qian LT; Hou XR; Zhang FQ; Zhang YJ; Zhu Y; Cao JZ; Lan SM; Wu JX; Wu T; Qi SN; Yang Y; Liu X; Li YX
Cancer Med; 2018 Dec; 7(12):5952-5961. PubMed ID: 30358175
[TBL] [Abstract][Full Text] [Related]
6. [Outcome of radiotherapy for low-risk early-stage patients with extranodal NK/T-cell lymphoma, nasal-type].
Wang XD; Liu X; Wu T; Yang Y; Qi SN; He X; Zhang LL; Wu G; Qu BL; Qian LT; Hou XR; Zhang FQ; Qiao XY; Wang H; Li GF; Zhu Y; Cao JZ; Wu JX; Zhu SY; Shi M; Su H; Zhang XM; Zhang HL; Huang HQ; Zhang YJ; Song YQ; Zhu J; Wang Y; Li YX
Zhonghua Zhong Liu Za Zhi; 2021 Oct; 43(10):1105-1113. PubMed ID: 34695903
[No Abstract] [Full Text] [Related]
7. Effect of age as a continuous variable on survival outcomes and treatment selection in patients with extranodal nasal-type NK/T-cell lymphoma from the China Lymphoma Collaborative Group (CLCG).
Liu WX; Shi M; Su H; Wang Y; He X; Xu LM; Yuan ZY; Zhang LL; Wu G; Qu BL; Qian LT; Hou XR; Zhang FQ; Zhang YJ; Zhu Y; Cao JZ; Lan SM; Wu JX; Wu T; Zhu SY; Qi SN; Yang Y; Chen B; Li YX
Aging (Albany NY); 2019 Oct; 11(19):8463-8473. PubMed ID: 31586991
[TBL] [Abstract][Full Text] [Related]
8. Risk-based, response-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: A China Lymphoma Collaborative Group study.
Qi SN; Yang Y; Zhang YJ; Huang HQ; Wang Y; He X; Zhang LL; Wu G; Qu BL; Qian LT; Hou XR; Zhang FQ; Qiao XY; Wang H; Li GF; Zhu Y; Cao JZ; Wu JX; Wu T; Zhu SY; Shi M; Xu LM; Yuan ZY; Su H; Song YQ; Zhu J; Hu C; Li YX
Am J Hematol; 2020 Sep; 95(9):1047-1056. PubMed ID: 32449800
[TBL] [Abstract][Full Text] [Related]
9. Primary site and regional lymph node involvement are independent prognostic factors for early-stage extranodal nasal-type natural killer/T cell lymphoma.
Niu SQ; Yang Y; Li YY; Wen G; Wang L; Li ZM; Wang HY; Zhang LL; Xia YF; Zhang YJ
Chin J Cancer; 2016 Apr; 35():34. PubMed ID: 27044275
[TBL] [Abstract][Full Text] [Related]
10. CD56-negative extranodal NK/T cell lymphoma should be regarded as a distinct subtype with poor prognosis.
Wang L; Wang Z; Xia ZJ; Lu Y; Huang HQ; Zhang YJ
Tumour Biol; 2015 Sep; 36(10):7717-23. PubMed ID: 25935537
[TBL] [Abstract][Full Text] [Related]
11. The correlation of clinicopathological features and prognosis in extranodal natural killer/T cell lymphoma: a report of 42 cases in the early stage.
Zeng L; Huang W; Cao Z; Zheng B; Liu X; Guo L; Feng X
Ann Hematol; 2019 Jun; 98(6):1467-1476. PubMed ID: 30895352
[TBL] [Abstract][Full Text] [Related]
12. Radiotherapy is essential after complete response to asparaginase-containing chemotherapy in early-stage extranodal nasal-type NK/T-cell lymphoma: A multicenter study from the China Lymphoma Collaborative Group (CLCG).
Deng XW; Wu JX; Wu T; Zhu SY; Shi M; Su H; Wang Y; He X; Xu LM; Yuan ZY; Zhang LL; Wu G; Qu BL; Qian LT; Hou XR; Zhang FQ; Zhang YJ; Zhu Y; Cao JZ; Lan SM; Dong M; Qi SN; Yang Y; Li YX
Radiother Oncol; 2018 Oct; 129(1):3-9. PubMed ID: 29739712
[TBL] [Abstract][Full Text] [Related]
13. Risk-Dependent Conditional Survival and Failure Hazard After Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell Lymphoma.
Liu X; Wu T; Zhu SY; Shi M; Su H; Wang Y; He X; Xu LM; Yuan ZY; Zhang LL; Wu G; Qu BL; Qian LT; Hou XR; Zhang FQ; Zhang YJ; Zhu Y; Cao JZ; Lan SM; Wu JX; Qi SN; Yang Y; Li YX
JAMA Netw Open; 2019 Mar; 2(3):e190194. PubMed ID: 30821826
[TBL] [Abstract][Full Text] [Related]
14. Retrospective analysis of treatment outcomes for extranodal NK/T-cell lymphoma (ENKL), nasal type, stage I-IIE: single institute experience of combined modality treatment for early localized nasal extranodal NK/T-cell lymphoma (ENKL).
Lee J; Cho SG; Chung SM; Ryu MR; Kim SH; Jang HS; Choi BO
Ann Hematol; 2013 Mar; 92(3):333-43. PubMed ID: 23180438
[TBL] [Abstract][Full Text] [Related]
15. Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell Lymphoma.
Yhim HY; Kim JS; Mun YC; Moon JH; Chae YS; Park Y; Jo JC; Kim SJ; Yoon DH; Cheong JW; Kwak JY; Lee JJ; Kim WS; Suh C; Yang DH;
Biol Blood Marrow Transplant; 2015 Sep; 21(9):1597-604. PubMed ID: 25963920
[TBL] [Abstract][Full Text] [Related]
16. Extranodal NK/T-cell lymphoma, nasal type: Clinical features, outcome, and prognostic factors in 101 cases.
Su YJ; Wang PN; Chang H; Shih LY; Lin TL; Kuo MC; Chuang WY; Wu JH; Tang TC; Hung YS; Dunn P; Kao HW
Eur J Haematol; 2018 Sep; 101(3):379-388. PubMed ID: 29908084
[TBL] [Abstract][Full Text] [Related]
17. Prognostic indicators of survival in sinonasal extranodal natural killer/T-cell lymphoma.
Varelas AN; Ganti A; Eggerstedt M; Tajudeen BA
Laryngoscope; 2019 Dec; 129(12):2675-2680. PubMed ID: 30801751
[TBL] [Abstract][Full Text] [Related]
18. Progression-free survival at 24 months as a predictor of survival outcomes after CHOP treatment in patients with peripheral T-cell lymphoma: a single-center validation study in a Japanese population.
Shirouchi Y; Yokoyama M; Fukuta T; Uryu H; Nishimura N; Mishima Y; Inoue N; Tsuyama N; Takeuchi K; Terui Y
Leuk Lymphoma; 2021 Aug; 62(8):1869-1876. PubMed ID: 33688781
[TBL] [Abstract][Full Text] [Related]
19. Serum EBV EA-IgA and VCA-IgA antibodies can be used for risk group stratification and prognostic prediction in extranodal NK/T cell lymphoma: 24-year experience at a single institution.
Huang Y; Rao H; Yan S; Wang F; Wu Q; Feng Y; Zhang Y
Ann Hematol; 2017 Aug; 96(8):1331-1342. PubMed ID: 28550598
[TBL] [Abstract][Full Text] [Related]
20. "Sandwich" Chemotherapy (CT) with Radiotherapy (RT) improves outcomes in patients with stage IE/IIE extranodal natural killer (NK)/T-cell Lymphomas.
Zhang J; Zhu MY; Wang L; Wang H; Wang WD; Geng QR; Lu Y
Asian Pac J Cancer Prev; 2013; 14(7):4061-6. PubMed ID: 23991953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
